Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

363
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
363
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

606
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
606
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

427
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
427
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

488
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
488
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining the feasibility of self-administered relaxing acupressure for fatigue among adolescent and young adult cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Association of Pain With Mental and Physical Function in Patients With Chemotherapy-Induced Peripheral Neuropathy: A Secondary Analysis From Two Randomized Controlled Trials.

Muscle & nerve·2026
Same author

Preliminary study exploring the association between amygdala-ventral medial prefrontal-cortex connectivity and anxiety among adolescent and young adult cancer survivors.

BMC cancer·2025
Same author

Challenges in diagnosing and treating chronic exertional compartment syndrome: perspective from a student nurse with lower extremity pain.

Frontiers in physiology·2025
Same author

Exploring Chemotherapy-Induced Peripheral Neuropathy Severity Patterns in Young Adult Women with Breast Cancer Receiving Weekly or Dose Dense Paclitaxel.

European journal of cancer care·2025
Same author

Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel.

Oncology nursing forum·2025

Related Experiment Video

Updated: Nov 12, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.4K

CE: Chemotherapy-Induced Peripheral Neuropathy.

Robert Knoerl1

  • 1Robert Knoerl is an instructor in medicine at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston. Contact author: robert_knoerl@dfci.harvard.edu . The author acknowledges Grace Kanzawa-Lee, PhD, RN, and Marilyn J. Hammer, PhD, DC, RN, FAAN, for their critical review of the manuscript. The author and planners have disclosed no potential conflicts of interest, financial or otherwise.

The American Journal of Nursing
|March 18, 2021
PubMed
Summary
This summary is machine-generated.

Chemotherapy-induced peripheral neuropathy (CIPN) affects over 68% of patients undergoing neurotoxic chemotherapy. Early identification and management strategies, including patient education, can minimize CIPN

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.5K

Related Experiment Videos

Last Updated: Nov 12, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.4K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.5K

Area of Science:

  • Oncology
  • Neurology
  • Nursing

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect affecting over 68% of patients receiving neurotoxic chemotherapy.
  • CIPN symptoms, including numbness, tingling, and pain, can significantly impair physical function and necessitate chemotherapy dose reductions.
  • This condition impacts patients undergoing treatment for various cancers like breast, gastrointestinal, gynecologic, and hematologic malignancies.

Purpose of the Study:

  • To equip nurses with effective strategies for assessing, managing, and educating patients at risk for or experiencing CIPN.
  • To highlight the importance of proactive patient communication regarding CIPN before and during chemotherapy treatment.
  • To emphasize methods for minimizing CIPN's impact on physical function and treatment continuity.

Main Methods:

  • Review of current clinical practices and guidelines for CIPN management.
  • Discussion of nursing interventions for patient assessment and symptom control.
  • Emphasis on patient education strategies throughout the chemotherapy continuum.

Main Results:

  • Early identification and management of CIPN are crucial for preserving physical function and maintaining chemotherapy dosing.
  • Patient education and ongoing communication are key components of effective CIPN management.
  • Duloxetine 60 mg/day is currently the only American Society of Clinical Oncology-endorsed treatment for CIPN.

Conclusions:

  • Nurses play a vital role in managing CIPN through assessment, intervention, and education.
  • Proactive patient engagement and timely management can mitigate the long-term effects of CIPN.
  • Optimizing CIPN care can improve patient quality of life and treatment outcomes.